{"id":"de-130a-de-130a","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Increased iris pigmentation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DE-130A is a prostaglandin analog or related compound formulated for ocular delivery to lower intraocular pressure by enhancing uveoscleral outflow of aqueous humor. The drug is being developed by Santen SAS, a company specializing in ophthalmology, and is in Phase 3 clinical trials for glaucoma management.","oneSentence":"DE-130A is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:51.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04133311","phase":"PHASE3","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-04-10","conditions":"Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease","enrollment":386}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Catiolanze®"],"phase":"phase_3","status":"active","brandName":"DE-130A/DE-130A","genericName":"DE-130A/DE-130A","companyName":"Santen SAS","companyId":"santen-sas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DE-130A is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2023-11-15T00:00:00.000Z","mah":"Santen Oy","brand_name_local":"Catiolanze","application_number":"EMEA/H/C/005933"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}